Skip to main content
NewslettersWatchlist

Iteos Therapeutics Inc(ITOS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low8.05
Day High8.46
Open:8.09
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
PR Newswire
NCR Atleos Set to Join S&P SmallCap 600
PR Newswire
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
BayStreet.ca
Novel Mechanisms Leading the Charge in Fight Against Cancer, Opening Door to New Drugs & Therapies
Globe Newswire
iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update
Globe Newswire
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
Business Wire
Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer
Globe Newswire
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update
Globe Newswire
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
Globe Newswire
iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Globe Newswire
iTeos to Present at the Cowen 42nd Annual Health Care Conference
Globe Newswire
iTeos to Participate in Upcoming Investor Conferences in February
Globe Newswire
iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer
Globe Newswire
iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference
Globe Newswire
iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021
Business Wire
MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee
Globe Newswire
iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
Globe Newswire
iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021
Globe NewsWire
iTeos Therapeutics to Participate in Upcoming September Investor Conferences
Globe NewsWire
iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update
Globe NewsWire
iTeos to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 12, 2021

Profile

iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery and development of immuno-oncology therapeutics. iTeos Therapeutics Inc. is based in Cambridge, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.